Efficacy of liraglutide 3 mig therapy in obesity and associated diseases
Obesity is a chronic disease associated with cardiometabolic risk factors, primarily cardiovascular diseases and type 2 diabetes mellitus. In 2016,Russiaregistered a new drug for treating obese patients liraglutide 3.0 mg, which is an analogue of human glucagon-like peptide-1. Given the urgency of t...
Main Authors: | , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2018-03-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/2338 |